NCT00605280COMPLETEDanonymous

A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, In Parallel Groups, To Compare The Safety And Efficacy Of Intravitreous Injections Of 0.3 Mg Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks For 2 Years, To Sham Injections In Subjects With Diabetic Macular Edema (DME) Involving The Center Of The Macula With An Open-Label Macugen Year 3 Extension.

Sponsor

Source record

Pfizer

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Standard of Care, Macugen

Indication / condition

AI-normalized

Macular Edema Associated With Diabetes Mellitus

Intervention

Source record

Standard of Care, Macugen

Source & freshness

Source record

NCT ID

NCT00605280

Original source

ClinicalTrials.gov

Source last updated

Nov 16, 2018

Ingested at

Jun 07, 2026

Internal sync

Jun 07, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00605280

Title

A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, In Parallel Groups, To Compare The Safety And Efficacy Of Intravitreous Injections Of 0.3 Mg Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks For 2 Years, To Sham Injections In Subjects With Diabetic Macular Edema (DME) Involving The Center Of The Macula With An Open-Label Macugen Year 3 Extension.

Sponsor

Pfizer

Status

COMPLETED

Phase

PHASE2

Condition raw

Macular Edema Associated With Diabetes Mellitus

Condition normalized

Macular Edema Associated With Diabetes Mellitus

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Standard of Care, Macugen

Target normalized

Standard of Care, Macugen

Interventions

Standard of Care, Macugen

Public preview

Source record

The purpose of the study is to test whether Macugen injected into the eye improves vision in more patients than the currently existing standard of care laser therapy. The safety of Macugen compared to standard of care laser will also be evaluated.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, In Parallel Groups, To Compare The Safety And Efficacy Of Intravitreous Injections Of 0.3 Mg Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks For 2 Years, To Sham Injections In Subjects With Diabetic Macular Edema (DME) Involving The Center Of The Macula With An Open-Label Macugen Year 3 Extension.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00605280

Status

COMPLETED

Phase

PHASE2

Sponsor

Pfizer

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedNov 16, 2018

Internal syncJun 07, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00605280

Indication

Macular Edema Associated With Diabetes Mellitus

Modality

small molecule

Target

Standard of Care, Macugen

Intervention

Standard of Care, Macugen

Source record